Physician profile
Gerard E Kortekamp
NPI 1194785113
$1,271.22
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $625 · 2020: $251 · 2021: $14.63 · 2022: $341 · 2023: $38.59.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $38.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $38.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $236.54 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $181.85 | 2019-2023 | |
| Abbvie INC. | $162.83 | 2021-2022 | |
| Amgen INC. | $77.67 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.35 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $65.11 | 2019 | |
| Lilly USA, LLC | $53.33 | 2019-2022 | |
| Amarin Pharma, INC. | $53.06 | 2019-2020 | |
| Pfizer INC. | $49.47 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $45.84 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.32 | 2019-2022 | |
| Abbott Laboratories | $37.48 | 2019 | |
| Merck Sharp & Dohme LLC | $32.76 | 2019-2023 | Belsomra |
| Takeda Pharmaceuticals U.S.A., INC. | $29.82 | 2019 | |
| Boston Scientific Corporation | $26.09 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $19.34 | 2022 | |
| Pulmonx Corporation | $14.64 | 2022 | |
| Idorsia Pharmaceuticals US INC | $13.63 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.58 | 2022 | |
| Astellas Pharma US INC | $12.45 | 2019 | |
| Sanofi-Aventis U.S. LLC | $11.81 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $11.68 | 2019 | |
| Allergan, INC. | $11.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerard Kortekamp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.